Log In
BCIQ
Print this Print this
 

IMP321 (formerly ImmuFact IMP321)

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionNatural human T cell immunostimulatory factor derived from soluble lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Major histocompatibility complex class II (MHCII) ; Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$28.0M

$10.8M

$7.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/17/2014

$28.0M

$10.8M

$7.2M

10/14/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today